# C_2017019EN.01000401.xml

| 20.1.2017 | EN | Official Journal of the European Union | C 19/4 |
| --- | --- | --- | --- |

20.1.2017

EN

Official Journal of the European Union

C 19/4

---

Prior notification of a concentration

(Case M.8336 — Mitsubishi Chemical Holdings/Marubeni/Metro Pacific Investments/JV)

Candidate case for simplified procedure

(Text with EEA relevance)

(2017/C 19/04)

| 1. | On 13 January 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings LSI Medience Corporation (‘LSI’, of Japan), a subsidiary of Mitsubishi Chemical Holdings Corporation, the holding company of the Mitsubishi Chemical group of companies; Marubeni Corporation (‘Marubeni’, of Japan), and Metro Pacific Hospital Holdings, Inc. (‘MPHHI’, of the Philippines), a subsidiary of Metro Pacific Investments Corporation (‘MPIC’), acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of a joint venture providing clinical laboratory services and clinical reagents to hospitals in the Philippines by way of purchase of shares. |
| --- | --- |

1.

On 13 January 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings LSI Medience Corporation (‘LSI’, of Japan), a subsidiary of Mitsubishi Chemical Holdings Corporation, the holding company of the Mitsubishi Chemical group of companies; Marubeni Corporation (‘Marubeni’, of Japan), and Metro Pacific Hospital Holdings, Inc. (‘MPHHI’, of the Philippines), a subsidiary of Metro Pacific Investments Corporation (‘MPIC’), acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of a joint venture providing clinical laboratory services and clinical reagents to hospitals in the Philippines by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   LSI: provider of various medical services worldwide (primarily, in Japan) including clinical testing; the development and provision of in vitro diagnostic reagents and instruments; drug development support services; food sanitation analysis services and antidoping testing services. The wider Mitsubishi Chemical Group provides various performance products, industrial materials and healthcare products worldwide (primarily in Japan),
  —   Marubeni: wholesale provider of a range of industrial and consumer goods — specifically, food and consumer products; chemical and forest products; energy and metals; power projects and plants; transportation and industrial machinery,
  —   MPHHI: investment and management holding firm which invests in and operates (through its subsidiaries) real estate and infrastructure projects in the Philippines. MPHHI is part of MPIC’s hospital operations unit, operating and managing hospitals in the Philippines,
  —   the Joint Venture: supply of clinical laboratory services and clinical reagents to hospitals in the Philippines. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   LSI: provider of various medical services worldwide (primarily, in Japan) including clinical testing; the development and provision of in vitro diagnostic reagents and instruments; drug development support services; food sanitation analysis services and antidoping testing services. The wider Mitsubishi Chemical Group provides various performance products, industrial materials and healthcare products worldwide (primarily in Japan),

LSI

in vitro

—   Marubeni: wholesale provider of a range of industrial and consumer goods — specifically, food and consumer products; chemical and forest products; energy and metals; power projects and plants; transportation and industrial machinery,

Marubeni

—   MPHHI: investment and management holding firm which invests in and operates (through its subsidiaries) real estate and infrastructure projects in the Philippines. MPHHI is part of MPIC’s hospital operations unit, operating and managing hospitals in the Philippines,

MPHHI

—   the Joint Venture: supply of clinical laboratory services and clinical reagents to hospitals in the Philippines.

the Joint Venture

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in this Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8336 — Mitsubishi Chemical Holdings/Marubeni/Metro Pacific Investments/JV, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8336 — Mitsubishi Chemical Holdings/Marubeni/Metro Pacific Investments/JV, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---